Beyond I-131 targeting the OPG/RANK/RANKL axis may offer a novel therapeutic approach for malignant osteolytic pathologies [11], but currently there are no such studies specifically for thyroid cancer bone metastases. This evidence concerns the gene TNFSF11 and thyroid gland carcinoma.